Recce Pharmaceuticals more than doubles SPP target with A$4.4 million taking raise proceeds to A$12.4 million Posted on August 5, 2024September 25, 2024 by recce_com Recce Pharmaceuticals more than doubles SPP target with A$4.4 million taking raise proceeds to A$12.4 million
Recce scores US$2M deal from US Department of Defense for burn wound infections gel Posted on July 16, 2024September 25, 2024 by recce_com Recce scores US$2M deal from US Department of Defense for burn wound infections gel
Recce Pharmaceuticals granted US$2 million from US Department of Defense for RECCE® 327 Gel Posted on July 15, 2024September 25, 2024 by recce_com Recce Pharmaceuticals granted US$2 million from US Department of Defense for RECCE® 327 Gel
Recce Pharmaceuticals reports positive data from Phase 1/2 UTI/urosepsis rapid infusion clinical trial of RECCE® 327 Posted on June 28, 2024September 25, 2024 by recce_com Recce Pharmaceuticals reports positive data from Phase 1/2 UTI/urosepsis rapid infusion clinical trial of RECCE® 327
Recce Starts Phase 2 R327 Gel trial for bacterial skin infections Posted on June 25, 2024September 25, 2024 by recce_com Recce Starts Phase 2 R327 Gel trial for bacterial skin infections
Recce Pharmaceuticals lands WHO Antibacterial Products in Clinical Development listing for RECCE® 327 Posted on June 18, 2024September 25, 2024 by recce_com Recce Pharmaceuticals lands WHO Antibacterial Products in Clinical Development listing for RECCE® 327
Recce completes cohort dosing for Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial with fastest infusion times yet; key safety review inbound Posted on June 12, 2024September 25, 2024 by recce_com Recce completes cohort dosing for Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial with fastest infusion times yet; key safety review inbound
Recce wraps up IV UTI trial with fastest infusion times yet; key safety review inbound Posted on June 11, 2024September 25, 2024 by recce_com Recce wraps up IV UTI trial with fastest infusion times yet; key safety review inbound
Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market Posted on May 27, 2024September 25, 2024 by recce_com Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market
Recce Pharma heading closer to full efficacy data for flagship R327 Posted on May 15, 2024September 25, 2024 by recce_com Recce Pharma heading closer to full efficacy data for flagship R327
